HC Wainwright Comments on I-Mab's Q3 Earnings (NASDAQ:IMAB)

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for I-Mab from ($0.09) to ($0.05), maintaining a "Buy" rating and a price target of $7.00.
• I-Mab reported a quarterly earnings of ($0.07), exceeding analysts’ expectations of ($0.10), which indicates better-than-anticipated performance.
• Several institutional investors have increased their stakes in I-Mab, reflecting growing interest, with 38.38% of the stock now owned by such investors.

I-Mab Sponsored ADR (NASDAQ:IMAB - Free Report) - Equities research analysts at HC Wainwright upped their Q3 2025 earnings per share estimates for I-Mab in a report released on Thursday, August 21st. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.05) for the quarter, up from their prior estimate of ($0.09). HC Wainwright currently has a "Buy" rating and a $7.00 price target on the stock. The consensus estimate for I-Mab's current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for I-Mab's Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.23) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at ($0.53) EPS.

I-Mab (NASDAQ:IMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, August 20th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03.

IMAB has been the topic of a number of other research reports. Needham & Company LLC lifted their target price on I-Mab from $5.00 to $6.00 and gave the company a "buy" rating in a research report on Wednesday, August 20th. Wall Street Zen upgraded I-Mab from a "hold" rating to a "buy" rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $6.50.

I-Mab Trading Up 8.1%

I-Mab stock opened at $5.09 on Monday. I-Mab has a 12-month low of $0.60 and a 12-month high of $5.90. The business's 50-day moving average price is $2.81 and its two-hundred day moving average price is $1.66.

Hedge Funds Weigh In On I-Mab

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC lifted its stake in shares of I-Mab by 6.6% in the second quarter. SG Americas Securities LLC now owns 876,353 shares of the company's stock worth $2,121,000 after acquiring an additional 54,312 shares during the period. Stonepine Capital Management LLC acquired a new position in shares of I-Mab in the first quarter worth approximately $398,000. Cantor Fitzgerald L. P. acquired a new position in shares of I-Mab in the fourth quarter worth approximately $119,000. BNP Paribas Financial Markets acquired a new position in shares of I-Mab in the fourth quarter worth approximately $93,000. Finally, Millennium Management LLC lifted its stake in shares of I-Mab by 763.1% in the fourth quarter. Millennium Management LLC now owns 97,749 shares of the company's stock worth $83,000 after acquiring an additional 86,424 shares during the period. 38.38% of the stock is owned by institutional investors and hedge funds.

I-Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.